Dr. Nestler is the Nash Family Professor of Neuroscience at the
Mount Sinai School of Medicine in New York, where he serves as
Chair of the Department of Neuroscience and Director of the
Friedman Brain Institute. He received his B.A., Ph.D., and M.D.
degrees, and psychiatry residency training, from Yale University.
He served on the Yale faculty from 1987-2000, where he was the
Elizabeth Mears and House Jameson Professor of Psychiatry and
Neurobiology, and Director of the Division of Molecular Psychiatry.
He moved to Dallas in 2000 where he served as the Lou and Ellen
McGinley Distinguished Professor and Chair of the Department of
Psychiatry at The University of Texas Southwestern Medical Center
until moving to New York in 2008. Dr. Nestler is a member of the
Institute of Medicine and a Fellow of the American Academy of Arts
and Sciences. The goal of Dr. Nestler's research is to better
understand the molecular mechanisms of addiction and depression
based on work in animal models, and to use this information to
develop improved treatments of these disorders. Roger N. Rosenberg,
MD is a graduate of Northwestern University Medical School, With
Distinction, and was subsequently trained in Neurology with H.
Houston Merritt, MD at the Neurological Institute, Columbia
University, New York, was Chief Resident and then was a
Post-Doctoral Fellow with Nobel Laureate Marshall Nirenberg at the
NIH in the Laboratory of Biochemical Genetics. He is Board
Certified by the American Board of Psychiatry and Neurology. He is
holder of the Zale Distinguished Chair and Professor of Neurology
and Neurotherapeutics at the University of Texas Southwestern
Medical Center at Dallas since 1973 and developed the department
for 18 years as Chair from 1973-1991.
He described for the first time in 1975 Machado Joseph disease, an
autosomal dominant cerebellar degeneration, which produces
imbalance and impaired coordination, and showed it was due to a
unique expansion of DNA in the causal gene. It is the most common
inherited form of impaired coordination in the world and his
research has provided a genetic marker to eliminate it in large
families in future generations.
He has served as the Founding Director of the UT Southwestern NIH
funded Alzheimer's Disease Center and Principal Investigator of the
NIH Center Grant from 1987-2019.
He directs an active laboratory effort in Alzheimer's Disease. He
is developing a DNA A�42 trimer vaccine for Alzheimer's disease for
which he was awarded a US Patent "Amyloid Beta Gene Vaccines" in
January 2009. It has been tested in mouse, transgenic mouse, New
Zealand white rabbits and rhesus monkeys. The vaccine produces
effective anti-A�42 peptide antibody levels and is non-inflammatory
in all three species. The vaccine reduces by 40% A�42 peptide and
by 50% tau and phospho-tau in the brains of 3X AD Tg mice, the two
main pathologies of Alzheimer's disease, with high levels of
anti-A�42 antibody and with a non-inflammatory immune response. He
is preparing now a Phase 1 Clinical trial Grant - First in Human to
determine its effectiveness and safety in human subjects.
He has published 297 original scientific articles, chapters,
reviews, and editorials.
He served as Editor in Chief from 1997 through 2017 for JAMA
Neurology (formerly Archives of Neurology), a major international
neurology journal, published by the American Medical Association.
During his tenure, he raised the Impact Factor of the journal from
3.0 to 10.2, placing JAMA Neurology as #1 of all US publications in
neurology.
He is the founding editor of two of the landmark texts in
neuroscience. Rosenberg's Molecular and Genetic Basis of
Neurological and Psychiatric Disease, 5th edition, published in
2015 by Elsevier. The 6th edition will publish in 2020. The Atlas
of Clinical Neurology, 4th edition, has just been published.
He is a former President of the American Academy of Neurology,
former Vice-President of the American Neurological Association, an
Honorary Member of both organizations, and a Fellow of the American
Association for the Advancement of Science. He received the first
Science Medal in 2009 from the World Federation of Neurology for
his contributions to neuro-genetics, for his original clinical and
molecular genetics research on Machado-Joseph disease, and the
development of the DNA Abeta42 trimer vaccine for Alzheimer's
disease.
Ask a Question About this Product More... |